Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis-Reference-Cited by-同舟云学术

Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Published:2021-10-04 Issue:1 Volume:57 Page:31-37
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Pasvolsky Oren,Yeshurun Moshe,Fraser Raphael,Estrada-Merly Noel,Rozovski Uri,Shargian-Alon Liat^ORCID,Assal Amer^ORCID,Banerjee Rahul^ORCID,Bumma Naresh,Gale Robert Peter,Hagen Patrick,Holmberg Leona,Hossain Nasheed M.^ORCID,Lazarus Hillard M.^ORCID,Lee Cindy,Mian Hira^ORCID,Miller Kevin C.,Nathan Sunita^ORCID,Nagler Arnon,Nishihori Taiga^ORCID,Parrondo Ricardo D.,Patel Sagar^ORCID,Schroeder Mark A.^ORCID,Usmani Saad Z.,Wang Trent^ORCID,Wirk Baldeep^ORCID,Kumar Shaji^ORCID,Shah Nina,Qazilbash Muzaffar H.^ORCID,D’Souza Anita^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01455-y.pdf

Reference18 articles.

1. Sengsayadeth S, Malard F, Savani BN, Garderet L, Mohty M. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017;7:e545 https://doi.org/10.1038/bcj.2017.23. e-pub ahead of print 2017/03/25

2. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905. https://doi.org/10.1056/NEJMoa1402888. e-pub ahead of print 2014/09/04

3. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2016;108. https://doi.org/10.1093/jnci/djv342

4. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89. https://doi.org/10.1200/JCO.2017.72.6679. e-pub ahead of print 2017/07/26

5. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:2946–55. https://doi.org/10.1200/JCO.2011.39.6820

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of second salvage autologous transplantation in myeloma patients;Pathology and Oncology Research;2024-07-16

2. Advances in second hematopoietic stem cell transplantation;Frontiers in Immunology;2024-07-09

3. Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma;Oncohematology;2023-12-07

4. Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial;Transplantation and Cellular Therapy;2023-12

5. Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions;Oncology and Therapy;2022-02-01